What is the official ID of this bill?

The official print number for this legislation is S 3440.

When did the legislative process begin?

The process officially started on 2022-01-04.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/s3440/BILLS-117s3440is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Who is the primary sponsor?

The primary sponsor is Sen. Cruz, Ted [R-TX].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 3440

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Equal Access to Medicines and Medical Supplies for States

Q: What are the main provisions?

Key points include: The federal government cannot limit state access to key therapies, such as monoclonal antibodies. State orders for COVID-19 medical supplies cannot be overridden by federal orders. States can use relief funds to purchase supplies previously unavailable due to federal prioritization.

This bill aims to ensure that state governments have equal access to key therapies, such as monoclonal antibodies, and medical supplies needed to combat the COVID-19 pandemic. This means the federal government will not be able to limit states' access to these resources or prioritize its own contracts over state contracts. Additionally, states will be able to use existing relief funds to purchase essential supplies they previously couldn't acquire due to federal priorities.

Key points

The federal government cannot limit state access to key therapies, such as monoclonal antibodies.

State orders for COVID-19 medical supplies cannot be overridden by federal orders.

States can use relief funds to purchase supplies previously unavailable due to federal prioritization.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Print number: S 3440

Sponsor: Sen. Cruz, Ted [R-TX]

Process start date: 2022-01-04

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Equal Access to Medicines and Medical Supplies for States

Key Questions about Equal Access to Medicines and Medical Supplies for States